Comprehensive human cell engineering services supporting drug discovery, disease modeling, and translational research, from iPSC generation and gene editing to differentiation and specialized cell isolation.
iXCells provides integrated iPSC and human cell engineering services that enable predictive, scalable, and translationally relevant research. From donor tissue to assay-ready cells, our platform combines iPSC generation, CRISPR genome editing, differentiation, and primary cell isolation within one scientifically rigorous workflow.
By unifying these capabilities under a single scientific team, we reduce variability, accelerate timelines, and support both mechanistic discovery and high-throughput screening.
Built as an extension of your laboratory, our High-Throughput iPSC Production platform delivers hundreds to thousands of patient-derived iPSC lines with the scale, reproducibility, and scientific rigor required for modern drug discovery programs.
We generate high-quality, karyotype-normal induced pluripotent stem cells from healthy and disease-relevant samples to support drug discovery, disease modeling, regenerative research, and personalized medicine initiatives.
Our CRISPR/Cas9-based Genome Editing services enable precise knock-outs, knock-ins, SNP replacement, reporter integration, and targeted mutations in iPSCs and other cell lines to accelerate functional research and therapeutic development.
We provide scalable iPSC Differentiation services that transform pluripotent stem cells into specialized, disease-relevant human cell types for mechanistic studies, target validation, and screening applications.
Our scientists specialize in Custom Cell Isolation from human, mouse, and rat tissues — including diseased samples and PBMCs — delivering high-viability, high-yield primary cells tailored to your experimental workflow.
Despite major advances in biology, translating early discoveries into effective therapies remains difficult. Many programs fail not because targets lack promise, but because available models do not sufficiently reflect human disease biology or cannot scale into screening workflows.
iXCells supports discovery programs across the drug development lifecycle from disease modeling and target validation to screening and translational studies. Our iPSC platform allows teams to start with patient-relevant biology and continue into scalable experimental systems without changing model type or vendor.
